STRYKER CORP shareholders Q2 2022

STRYKER CORP's ticker is SYK and the CUSIP is 863667101. A total of 1,558 filers reported holding STRYKER CORP in Q2 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.5%.

STRYKER CORP shareholders Q2 2022
Name	Shares	Value	Weighting ↓
BRADLEY FOSTER & SARGENT INC/CT	162,262	$32,279,000	0.83%
MIDDLETON & CO INC/MA	32,418	$6,449,000	0.83%
Seelaus Asset Management LLC	5,579	$1,110,000	0.82%
Quilter Plc	120,954	$24,061,000	0.81%
CONGRESS ASSET MANAGEMENT CO /MA	418,995	$83,351,000	0.80%
STOCK YARDS BANK & TRUST CO	97,233	$19,343,000	0.80%
W.G. Shaheen & Associates DBA Whitney & Co	21,958	$4,368,000	0.79%
Carnegie Capital Asset Management, LLC	88,001	$17,506,000	0.79%
DUNCKER STREETT & CO INC	16,303	$3,243,000	0.78%
Marble Harbor Investment Counsel, LLC	25,627	$5,098,000	0.78%
Brown Miller Wealth Management, LLC	5,662	$1,126,000	0.77%
Boston Trust Walden Corp	406,769	$80,918,000	0.76%
CENTRAL BANK & TRUST CO	18,740	$3,728,000	0.76%
A. D. Beadell Investment Counsel, Inc.	4,585	$912,000	0.76%
BLAIR WILLIAM & CO/IL	851,936	$169,476,000	0.75%
MADISON WEALTH MANAGEMENT	15,548	$3,093,000	0.75%
NORTHCAPE WEALTH MANAGEMENT, LLC	9,788	$1,947,000	0.74%
Notis-McConarty Edward	8,950	$1,780,000	0.74%
STONNINGTON GROUP, LLC	13,723	$2,768,000	0.74%
MACKENZIE FINANCIAL CORP	2,309,931	$459,515,000	0.74%

About STRYKER CORP

Stryker Corp is a leading medical technology company that specializes in developing and manufacturing medical devices and equipment. The company has a strong reputation for innovation and has been at the forefront of developing new technologies that have revolutionized the healthcare industry.

Stryker Corp's product portfolio includes a wide range of medical devices and equipment, including surgical instruments, orthopedic implants, and medical imaging systems. The company's products are used in hospitals, clinics, and other healthcare facilities around the world.

One of the key strengths of Stryker Corp is its focus on research and development. The company invests heavily in R&D, and this has enabled it to develop a number of groundbreaking technologies that have helped to improve patient outcomes and reduce healthcare costs.

Another key strength of Stryker Corp is its strong financial position. The company has a solid balance sheet and generates strong cash flows, which has enabled it to invest in new technologies and pursue strategic acquisitions.

Looking ahead, Stryker Corp is well-positioned to continue to grow and expand its business. The company has a strong pipeline of new products and technologies, and is well-positioned to benefit from the growing demand for medical devices and equipment around the world.

Overall, Stryker Corp is a well-managed and innovative company that is poised for continued success in the years ahead.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists STRYKER CORP's shareholders in Q2 2022. To view STRYKER CORP's shareholder history, click here.